Theranostics Through the Synergistic Cooperation of Heterometallic Complexes

A critical analysis of the potential of iron heterobimetallic complexes in anticancer research

Due to their diverse chemical properties and high ability to interact with biological molecules and cellular processes, transition metal-based compounds have emerged as promising candidates for cancer therapy. Iron complexes are among them, however, there is a gap in the comprehensive analysis of heterometallic iron complexes in the anticancer field. This review aims to fill this gap by summarizing recent progress in the study of Fe(II) and Fe(III) heterobimetallic complexes for anticancer applications and to gather important insights and future perspectives, with special emphasis on their theranostic capabilities. Works published between 2014 and 2024 were considered in this critical survey, that covers a range of complex types, including ferrocene in bimetallic complexes with Pt, Pd, Au, Ag, Ru, Rh, Ir, Cu, Re, Sn and Co; organometallic Fe-complexes with Ru and Ag; photoactive metal complexes with Pt and Co; and magnetic resonance imaging contrast agents with Gd and Mn. Studies conducted to determine the modes of action are highlighted and suggest the involvement of the metal species in reactive oxygen species generation within cells, the impact on apoptosis and cell cycle arrest, and many others. By pursuing interdisciplinary research, innovative theranostic platforms with enhanced efficacy, specificity, and clinical relevance can be developed for cancer management.

Comparative study of the antiproliferative activity of heterometallic carbene gold(i)-platinum(ii) and gold(i)-palladium(ii) complexes in cancer cell lines

The stepwise, one-pot synthesis of heterobimetallic carbene gold(i) platinum(ii) complexes from readily available starting materials is presented. The protecting group free methodology is based on the graduated nucleophilicities of aliphatic and aromatic amines as linkers between both metal centers. This enables the selective, sequential installation of the metal fragments. In addition, the obtained complexes were tested as potential anticancer agents and directly compared to their gold(i) palladium(ii) counterparts.

Heteronuclear Complexes with Promising Anticancer Activity against Colon Cancer

This study investigates the activity of novel gold(I) and copper(I)/zinc(II) heteronuclear complexes against colon cancer. The synthesised heteronuclear Au(I)-Cu(I) and Au(I)-Zn(II) complexes were characterised and evaluated for their anticancer activity using human colon cancer cell lines (Caco-2). The complexes exhibited potent cytotoxicity, with IC50 values in the low micromolar range, and effectively induced apoptosis in cancer cells. In the case of complex [Cu{Au(Spy)(PTA)}2]PF6 (2), its cytotoxicity is ×10 higher than its mononuclear precursor, while showing low cytotoxicity towards differentiated healthy cells. Mechanistic studies revealed that complex 2 inhibits the activity of thioredoxin reductase, a key enzyme involved in redox regulation, leading to an increase in reactive oxygen species (ROS) levels and oxidative stress, in addition to an alteration in DNA's tertiary structure. Furthermore, the complexes demonstrated a strong binding affinity to bovine serum albumin (BSA), suggesting the potential for effective drug delivery and bioavailability. Collectively, these findings highlight the potential of the investigated heteronuclear Au(I)-Cu(I) and Au(I)-Zn(II) complexes as promising anticancer agents, particularly against colon cancer, through their ability to disrupt redox homeostasis and induce oxidative stress-mediated cell death.

DNA-Targeted Complexes of Tc and Re for Biomedical Applications

Due to their favorable chemical features, Re and Tc complexes have been widely used for the development of new therapeutic agents and imaging probes to solve problems of biomedical relevance. This review provides an update of the most relevant research efforts towards the development of novel cancer theranostic agents using Re and Tc-based compounds interacting with specific DNA structures. This includes a variety of homometallic complexes, namely those containing M(CO)3 (M=Re, Tc) moieties, that exhibit different modes of interaction with DNA, such as covalent binding, intercalation, groove binding or G-quadruplex DNA binding. Additionally, heterometallic complexes, designed to potentiate synergistic effects of different metal centers to improve DNA-targeting, cytotoxicity and fluorescence properties, are also reviewed. Particular attention is also given to 99m Tc- and 188 Re-labeled oligonucleotides that have been widely explored to develop imaging and therapeutic radiopharmaceuticals through the in vivo hybridization with a specific complementary DNA or RNA target sequence to provide useful molecular tools in precision medicine for cancer diagnosis and treatment. Finally, the need for further improvement of DNA-targeted Re and Tc-based compounds as potential therapeutic and diagnostic agents is highlighted, and future directions are discussed.

Metals in Cancer Research: Beyond Platinum Metallodrugs

The discovery of the medicinal properties of platinum complexes has fueled the design and synthesis of new anticancer metallodrugs endowed with unique modes of action (MoA). Among the various families of experimental antiproliferative agents, organometallics have emerged as ideal platforms to control the compounds' reactivity and stability in a physiological environment. This is advantageous to efficiently deliver novel prodrug activation strategies, as well as to design metallodrugs acting only via noncovalent interactions with their pharmacological targets. Noteworthy, another justification for the advance of organometallic compounds for therapy stems from their ability to catalyze bioorthogonal reactions in cancer cells. When not yet ideal as drug leads, such compounds can be used as selective chemical tools that benefit from the advantages of catalytic amplification to either label the target of interest (e.g., proteins) or boost the output of biochemical signals. Examples of metallodrugs for the so-called "catalysis in cells" are considered in this Outlook together with other organometallic drug candidates. The selected case studies are discussed in the frame of more general challenges in the field of medicinal inorganic chemistry.

Synthesis and luminescent properties of hetero-bimetallic and hetero-trimetallic Ru(II)/Au(I) or Ir(III)/Au(I) complexes

A series of Ru(II) and Ir(III) based photoluminescent complexes were synthesised that incorporate an ancillary 2,2'-bipyridine ligand adorned with either one or two pendant N-methyl imidazolium groups. These complexes have been fully characterised by an array of spectroscopic and analytical techniques. One Ir(III) example was unequivocally structurally characterised in the solid state using single crystal X-ray diffraction confirming the proposed formulation and coordination sphere. These complexes were then transformed into their heterometallic, Au(I)-containing, analogues in two steps to yield either bi- or trimetallic complexes that integrate {Au(PPh3)}+ units. X-ray diffraction was used to corroborate the solid state structure of the hetero bimetallic complex, based upon a Ru(II)-Au(I) species. The heterometallic complexes all displayed red photoluminescent features (λem = 616-629 nm) that were consistent with the parent Ru(II) or Ir(III) lumophores in each case. The modulation of the emission from the Ru(II)-Au(I) complexes was much more strongly evident than for the Ir(III)-Au(I) analogues, which is ascribed to the inherent differences in the specific triplet excited state character of the emitting states within each heterometallic species.

Unusual Effects of the Metal Center Coordination Mode on the Photophysical Behavior of the Rhenium(I) and Rhenium(I)-Iridium(III) Complexes

Binuclear transition-metal complexes based on conjugated systems containing coordinating functions are potentially suitable for a wide range of applications, including light-emitting materials, sensors, light-harvesting systems, photocatalysts, etc., due to energy-transfer processes between chromophore centers. Herein we report on the synthesis, characterization, photophysical, and theoretical studies of relatively rare rhenium(I) and rhenium(I)-iridium(III) dyads prepared by using the nonsymmetrical polytopic ligands (NN2 and NN3) with the strongly conjugated phenanthroline and imidazole-quinoline/pyridine coordinating fragments. Availability of these different diimine chelating functions and targeted synthetic procedures allowed one to obtain a series of mononuclear (Re and Ir) and binuclear (Re-Re and Re-Ir) metal complexes with various modes of {Re(CO)3Cl} and {Ir(NC)2} metal fragment coordination. The obtained compounds were characterized by 1D 1H and 2D (COSY and NOESY) NMR spectroscopy, mass spectrometry, elemental analysis, and X-ray diffraction crystallography. The photophysical study of the complexes (absorption, excitation and emission spectra, quantum yields, and excited-state lifetimes) showed that their emission parameters display strong dependence on the manner of metal center coordination to the diimine bidentate functions. The mononuclear complexes with an unoccupied imidazole-quinoline/pyridine fragment [Re(NN2), Re(NN3), and Ir(NC2)2(NN2)] or those containing a coordinated {Ir(NC)2} fragment in this position [Ir(NC2)2(NN1) and Re(NN2)Ir(NC1)2-Re(NN2)Ir(NC4)2] exhibit moderate-to-intense phosphorescence (quantum yields vary from 3% to 56% in a degassed solution), whereas the complexes containing a {Re(CO)3Cl} moiety in the imidazole-quinoline/pyridine position [Re2(NN2), Re2(NN3), and Ir(NC2)2(NN2)Re] demonstrate a strong reduction in the phosphorescence efficiency with a quantum yield of ≪0.1%. Quenching of the phosphorescence in the latter types of emitters is discussed in terms of a strong decrease in the radiative rate constants for these complexes compared to their analogues mentioned above, while the nonradiative constants remain nearly unchanged. Theoretical density functional theory (DFT) and time-dependent DFT (TD DFT) calculations, including evaluation of the radiative rate constants for the couple of structurally analogous complexes with and without a {Re(CO)3Cl} moiety coordinated to the imidazole-quinoline/pyridine chelating function, confirmed the observed trend in the variation of the emission intensity.

Promising heterometallic compounds as anticancer agents: Recent studies in vivo

Over the past decade, interest on multitarget anticancer drugs -including heterometallic compounds-has increased considerably. Heterometallic species display improved efficacy and physicochemical properties compared to the individual metallic fragments for a variety of metal pair combinations. By 2018, several compounds had emerged as promising candidates against cisplatin resistant cancers. Here, we summarize research contributions to this topic over the past four years (July 2018-July 2022). In particular, we highlight five articles reporting on the in vivo activity and preliminary mechanisms of action for five groups of compounds. From this selection, we further feature two families of compounds based on Pt(IV)-Gd(III) and Ti(IV)-Au(I) metal combinations, given their potential for clinical translation.

Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments

Although important progress has been made, cancer still remains a complex disease to treat. Serious side effects, the insurgence of resistance and poor selectivity are some of the problems associated with the classical metal-based anti-cancer therapies currently in clinical use. New treatment approaches are still needed to increase cancer patient survival without cancer recurrence. Herein, we reviewed two promising-at least in our opinion-new strategies to increase the efficacy of transition metal-based complexes. First, we considered the possibility of assembling two biologically active fragments containing different metal centres into the same molecule, thus obtaining a heterobimetallic complex. A critical comparison with the monometallic counterparts was done. The reviewed literature has been divided into two groups: the case of platinum; the case of gold. Secondly, the conjugation of metal-based complexes to a targeting moiety was discussed. Particularly, we highlighted some interesting examples of compounds targeting cancer cell organelles according to a third-order targeting approach, and complexes targeting the whole cancer cell, according to a second-order targeting strategy.

Tunable Emissive Ir(III) Benzimidazole-quinoline Hybrids as Promising Theranostic Lead Compounds

Bioactive and luminescent cyclometallated Ir(III) complexes [Ir(ppy)₂ L1]Cl (1) and [Ir(ppy)₂ L2]Cl (2) containing a benzimidazole derivative (L1/L2) as auxiliary mimic of a nucleotide have been synthesised. The emissive properties of both complexes are conditioned by the nature of L1 and L2, rendering an orange and a green emitter respectively. Both are highly emissive with quantum yield increasing in absence of oxygen up to 0.26 (1) and 0.36 (2), suggesting their phosphorescent character. Antiproliferative activity against lung cancer A549 cells increased up to 15 times upon irradiation conditions, reaching IC₅₀ values in the nanomolar range (0.3±0.09 μM (1) and 0.26±0.14 μM (2)) and pointing them as good PSs candidates for photodynamic therapy via ¹ O₂ generation. Cellular biodistribution analysis by fluorescence microscopy suggest the lysosomes as the preferential accumulation organelle. Time-resolved studies showed a greatly increased cellular emission lifetime compared to the solution values, indicating binding to macromolecules or cellular structures and restriction of collision and vibrational quenching.

Gold(I) metallocyclophosphazenes with antibacterial potency and antitumor efficacy. Synergistic antibacterial action of a heterometallic gold and silver-cyclophosphazene

One of the most important uses of phosphazenes today involves its biomedical applications. They can also be employed as scaffolds for the design and construction of a variety of ligands in order to coordinate them to metallic drugs. The coordination chemistry of the (amino)cyclotriphosphazene ligand, [N₃P₃(NHCy)₆], towards gold(I) complexes has been studied. Neutral complexes, [N₃P₃(NHCy)₆{AuX}_n] (X = Cl or C₆F₅; n = 1 or 2) (1-4), cationic complexes, [N₃P₃(NHCy)₆{Au(PR₃)}_n](NO₃)_n (PR₃ = PPh₃, PPh₂Me, TPA; n = 1, 2 or 3) (6-12) [TPA = 1,3,5-triaza-7-phosphaadamantane] and a heterometallic compound [N₃P₃(NHCy)₆{Au(PPh₃)}₂{Ag(PPh₃)}](NO₃)₃ (13) have been obtained and characterized by various methods including single-crystal X-ray diffraction for 7, which confirms the coordination of gold atoms to the nitrogens of the phosphazene ring. Compounds 1, 4, 6-13 were screened for in vitro cytotoxic activity against two tumor human cell lines, MCF7 (breast adenocarcinoma) and HepG2 (hepatocellular carcinoma), and for antimicrobial activity against five bacterial species including Gram-positive, Gram-negative, and Mycobacteria. Both the median inhibitory concentration (IC₅₀) and minimum inhibitory concentration (MIC) values are among the lowest found for any gold or silver derivatives against the cell lines and particularly against the Gram-positive (S. aureus) strain and the mycobacteria used in this work. Structure-activity relationships are discussed in order to determine the influence of ancillary ligands and the number and type of metal atoms (silver or gold). Compounds 4 and 8 showed not only maximal potency on human cells but also some tumour selectivity. Remarkably, compound 13, with both gold and silver atoms, showed outstanding activity against both Gram-positive and Gram-negative strains (nanomolar range), thus having a cooperative effect between gold and silver, with MIC values which are similar or lower than those of gentamicine, ciprofloxacin and rifampicine. The broad spectrum antimicrobial efficacy of all these metallophosphazenes and particularly of heterometallic compound 13 could be very useful to obtain materials for surfaces with antimicrobial properties that are increasingly in demand.

A novel heterometallic ruthenium-silver complex as potential antitumor agent: Studies on its synthesis, in vitro assays and interactions with biomolecular targets

Certain ruthenium compounds are found to be potent growth inhibitors for cancer cells. In the current study, a novel ruthenium-triphenylphosphine (PPh₃) cation and silver-2-mercapto nicotinate acid (H₂mna) anion complex (RSC) was synthesized, and its molecular structure was determined by IR, NMR and X-ray crystallography. Biological assays revealed that RSC strongly inhibited the viability of MCF-7 and MDA-MB-231 cells with IC₅₀ values of 9.6±1.1 and 7.5±0.8 µM, respectively, and significantly blocked their migration rates. Ultraviolet spectroscopy and fluorescence emission experiments demonstrated that RSC interacted with BSA, but not DNA. Further studies on [Ag₆(Hmna)₂(mna)₄]^4- binding with BSA and DNA found the anion did not interact with these biomolecules, indicating that RSC exerted its biological functions through its ruthenium-PPh₃ complex (RTC) moiety, and molecular docking provided additional evidence supporting this result. Fluorescence resonance energy transfer showed that the number of binding sites (n) and binding constant of RTC-BSA complex were 1 and 8.60 × 10⁴ M^-1 at 310K, suggesting a strong interaction between RTC and BSA. The thermodynamic parameters ΔG⁰, ΔH⁰ and ΔS⁰ of the binding were calculated, and it was demonstrated that the binding of RTC with BSA was enthalpy-driven, and the main forces between RTC and BSA were electrostatic force and hydrogen bonding. Molecular docking showed that the binding site of BSA with RSC was located on the interface between the domains IIA and IIB of the protein. The present study sheds light on that a ruthenium mono-coordinated with PPh₃ complex could help to design and develop a new class of antitumor drugs.

Challenges and opportunities in the development of metal-based anticancer theranostic agents

Around 10 million fatalities were recorded worldwide in 2020 due to cancer and statistical projections estimate the number to increase by 60% in 2040. With such a substantial rise in the global cancer burden, the disease will continue to impose a huge socio-economic burden on society. Currently, the most widely used clinical treatment modality is cytotoxic chemotherapy using platinum drugs which is used to treat variety of cancers. Despite its clinical success, critical challenges like resistance, off-target side effects and cancer variability often reduce its overall therapeutic efficiency. These challenges require faster diagnosis, simultaneous therapy and a more personalized approach toward cancer management. To this end, small-molecule ‘theranostic’ agents have presented a viable solution combining diagnosis and therapy into a single platform. In this review, we present a summary of recent efforts in the design and optimization of metal-based small-molecule ‘theranostic’ anticancer agents. Importantly, we highlight the advantages of a theranostic candidate over the purely therapeutic or diagnostic agent in terms of evaluation of its biological properties.

Synthetic Strategy Towards Heterodimetallic Half-Sandwich Complexes Based on a Symmetric Ditopic Ligand

Multimetallic complexes have been shown in several examples to possess greater anticancer activity than their monometallic counterparts. The increased activity has been attributed to altered modes of action. We herein report the synthesis of a series of heterodimetallic compounds based on a ditopic ligand featuring 2-pyridylimine chelating motifs and organometallic half-sandwich moieties. The complexes were characterized by a combination of ¹H NMR spectroscopy, electrospray ionization mass spectrometry, elemental analysis and single crystal X-ray diffraction. Investigations into the stability of representative complexes in DMSO-d₆ and 10% DMSO-d₆/D₂O revealed the occurrence of solvent-chlorido ligand exchange. Proliferation assays in four human cancer cell lines showed that the Os-Rh complex possessed minimal activity, while all other complexes were inactive.

Aggregation versus Biological Activity in Gold(I) Complexes. An Unexplored Concept

The aggregation process of a series of mono- and dinuclear gold(I) complexes containing a 4-ethynylaniline ligand and a phosphane at the second coordination position (PR3-Au-C≡CC6H4-NH2, complexes 1-5, and (diphos)(Au-C≡CC6H4-NH2)2, complexes 6-8), whose biological activity was previously studied by us, has been carefully analyzed through absorption, emission, and NMR spectroscopy, together with dynamic light scattering and small-angle X-ray scattering. These experiments allow us to retrieve information about how the compounds enter the cells. It was observed that all compounds present aggregation in fresh solutions, before biological treatment, and thus they must be entering the cells as aggregates. Inductively coupled plasma atomic emission spectrometry measurements showed that mononuclear complexes are mainly found in the cytosolic fraction; the dinuclear complexes are mainly found in a subsequent fraction composed of nuclei and cytoskeleton. Additionally, dinuclear complex 8 affects the actin aggregation to a larger extent, suggesting a cooperative effect of dinuclear compounds.

Multifunctional Heterometallic IrIII -AuI Probes as Promising Anticancer and Antiangiogenic Agents

A new class of emissive cyclometallated IrIII -AuI complexes with a bis(diphenylphosphino) methanide bridging ligand was successfully synthesised from the diphosphino complex [Ir(N^C)2 (dppm)]+ (1). The different gold ancillary ligand, a triphenylphosphine (2), a chloride (3) or a thiocytosine (4) did not reveal any significant effect on the photophysical properties, which are mainly due to metal-to-ligand charge-transfer (3 MLCT) transitions based on IrIII . However, the AuI fragment, along with the ancillary ligand, seemed crucial for the bioactivity in A549 lung carcinoma cells versus endothelial cells. Both cell types display variable sensitivities to the complexes (IC50 =0.6-3.5 μM). The apoptotic pathway is activated in all cases, and paraptotic cell death seems to take place at initial stages in A549 cells. Species 2-4 showed at least dual lysosomal and mitochondrial biodistribution in A549 cells, with an initial lysosomal localisation and a possible trafficking process between both organelles with time. The bimetallic IrIII -AuI complexes disrupted the mitochondrial transmembrane potential in A549 cells and increased reactive oxygen species (ROS) generation and thioredoxin reductase (TrxR) inhibition in comparison with that displayed by the monometallic complex 1. Angiogenic activity assays performed in endothelial cells revealed the promising antimetastatic potential of 1, 2 and 4.

Near-infrared emitting fluorescent homobimetallic gold(I) complexes displaying promising in vitro and in vivo therapeutic properties

Three near-infrared (NIR-I) optical theranostic systems were synthesized, characterized and studied in vitro and in vivo. These original homo-bimetallic gold(I)-based aza-BODIPY complexes proved to be trackable through near-infrared optical imaging in cells and in mice. They display anti-proliferative properties in micromolar range against human and murine cancer cell lines (4T1, MDA-MB-231, CT26, and SW480). Moreover, the injection of the most promising theranostic agent in CT26 tumor-bearing BALB/c mice induced a significant anti-cancer activity.